Alpha-9 Theranostics Announces Oversubscribed $75 Million Series B Financing to Advance Portfolio of Radiopharmaceuticals for Cancer

Company is developing bespoke radiopharmaceuticals with capital efficient and rapid approach

Proceeds to support progression of five candidates into the clinic, expansion of early-stage programs, accelerated growth of team, and completion of purpose-built research facilities

BOSTON, Mass. and VANCOUVER, British Columbia, December 14, 2022Alpha-9 Theranostics Inc., a clinical stage company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer, today announced an oversubscribed $75 million Series B financing. The round was led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital and Quark Venture in addition to existing investors Longitude Capital and BVF Partners.

Alpha-9 is engineering highly effective, bespoke radiopharmaceuticals for the treatment of solid and hematologic malignancies. These molecules are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. The Series B funding will support advancement of the company’s five programs into the clinic over the next two years while expanding its early-stage programs.

“We have always believed in the company, its founders, and the potential for radiotherapies to effectively address a wide range of cancers,” said David Hirsch, M.D., Ph.D., Chief Executive Officer of Alpha-9. “Our team has done excellent work progressing our pipeline of novel radiopharmaceuticals over the last year, and we are excited to have the support of these top-tier investors. With this new investor partnership, we are well positioned to progress multiple targets into the clinic, harnessing the potential of radiopharmaceuticals to realize more effective treatments for people living with cancer.”

Alpha-9’s systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Leveraging its founders’ deep expertise in the modification of peptides and small molecules, Alpha-9 tailors each component of its radiopharmaceuticals – binder, linker, chelator and radioisotope – to improve the molecule’s overall performance. The company’s development process includes human imaging and dosimetry studies, which provide early feedback on molecule design. This approach is capital efficient and rapid, resulting in de-risked compounds prior to later-stage clinical evaluation.

“The radiopharmaceutical field has evolved over the past several years, attributable to scientific advances, translational data and strong clinical efficacy,” said Melissa McCracken, Ph.D., Partner at Nextech Invest and Alpha-9 Board member. “This new generation of radiopharmaceuticals shows improved tumor uptake with limited off-target exposure, resulting in drugs that have better safety and efficacy profiles in the clinic. We are excited by the progress Alpha-9 has demonstrated and are proud to support expansion of its programs and facilities.”

In addition to advancing the clinical pipeline, the Series B will enable Alpha-9 to grow its team to support discovery programs. Furthermore, the company will complete the build-out of its research facilities in Vancouver, BC, which will house the chemistry, biology, translational research and radiochemistry teams, as well as support product formulation. Alpha-9 has also invested in radioisotope supply through agreements with multiple lutetium and actinium partners. The company looks forward to expanding these relationships with the Series B proceeds.

The company, headquartered in both Boston and Vancouver, was founded in 2019 by François Bénard, M.D., Kuo-Shyan Lin, Ph.D., and David Perrin, Ph.D., leading researchers from BC Cancer and the University of British Columbia with deep expertise in the modification of peptides and small-molecules to create novel radiopharmaceuticals.

Melissa McCracken, Ph.D., Partner at Nextech Invest, Patrick Heron, M.B.A., Managing Partner at Frazier Life Sciences, Cory Freedland, Ph.D., Partner at Samsara BioCapital, and Matthew Young, M.B.A., Managing Director at Longitude Capital will join the Alpha-9 Board of Directors, along with Darcy Mootz, Ph.D., Site Head at Amunix, a Sanofi Company (Chief Business Officer prior to sale), who will join as a Board advisor.

About Alpha-9 Theranostics

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers. For more information, please visit www.alpha9tx.com.

Media Contact

Joan Bosisio, Verge Scientific Communications
jbosisio@vergescientific.com

Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

BOSTON, Mass. and VANCOUVER, British Columbia, October 13, 2022 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Alpha-9 Theranostics Inc. (Alpha-9), a radiopharmaceutical company with offices in Vancouver and Boston, have signed an agreement for the preferred supply of GMP grade Actinium-225. The reservation gives Alpha-9 priority access to Eckert & Ziegler’s high-purity, non-carrier-added Actinium-225, a radionuclide used for the next generation of therapeutic radiopharmaceuticals.

“Following the successful completion of our supply agreement for Lutetium-177 earlier this year, we are pleased to further expand our relationship with Alpha-9 and contribute to innovation in cancer treatment through the supply of Actinium-225, a promising therapeutic radioisotope” explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “Access to Actinium-225 has been limited in the past which slowed down clinical research and commercial use. With the construction of our new Ac-225 production facility, we are addressing this situation and expect to be able to offer the radioisotope in limited quantities in the fourth quarter of 2023 and in larger quantities in the second half of 2024.”

“The radionuclide Actinium-225 is a key component of the therapeutic compounds in our portfolio and access is crucial to drive our development and clinical research” stated David Hirsch, CEO of Alpha-9. “We are pleased to extend our collaboration with Eckert & Ziegler to achieve our goal of improving the lives of patients affected by metastatic cancers.”

Actinium-225 is used as an active substance in cancer treatment. The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells, including elusive micrometastases, with minimal impact on surrounding healthy tissue. For this purpose, Actinium-225 is combined with a suitable carrier (e.g., an antibody or peptide) that specifically binds to cancer cells, thereby selectively targeting them. Currently, radiopharmaceuticals based on Actinium-225 are being tested in many clinical indications, including prostate tumors, colorectal cancer and leukemia. Experts expect the demand for Actinium-225 to increase exponentially over the next decade.

About Eckert & Ziegler.

Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse. Contributing to saving lives.

About Alpha-9 Theranostics

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles.

Alpha-9 Starts Construction of Research Facility in Vancouver

VANCOUVER, British Columbia, October 1, 2022 – Alpha-9 Theranostics, Inc. announced today that it has authorized construction of an in-house research facility in Vancouver, British Columbia.

The fit-for-purpose facility will house chemistry, biology and radiochemistry R&D teams, and will accelerate Alpha-9’s discovery efforts for new peptide and small molecule-based radiopharmaceuticals. The facility will house hot cells to develop Alpha-9’s radiolabeling processes at clinical scale for subsequent transfer to the company’s GMP manufacturing partners, facilitating clinical translation of the company’s product candidates. Planning has been underway since earlier this year and the research facilities are expected to be operational by 2H 2023

Isotopia Molecular Imaging and Alpha-9 Theranostics Announce Lutetium-177 Supply Agreement

BOSTON, Mass. and VANCOUVER, British Columbia, May 23, 2022 – Isotopia Molecular Imaging and Alpha-9 Theranostics, are pleased to announce the signing of a global clinical supply agreement that provides Alpha-9 with Isotopia’s medical radioisotope no-carrier-added lutetium-177 for the preclinical and clinical development of Alpha-9’s radiopharmaceutical pipeline.

“We are pleased to contribute to Alpha-9’s exciting program,” comments Director of BD Keren Moshkoviz. “Using our  well established experience in radioisotope global production and supply, we aim to further support the development of Targeted Radionuclide Therapies to improve clinical outcomes for patients worldwide.”

Alpha-9 is excited to partner with Isotopia and is committed to developing its pipeline of radiopharmaceuticals for the benefit of patients.

Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

BOSTON, Mass. and VANCOUVER, British Columbia, March 23, 2022 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of Alpha-9´s investigational drugs.

Eckert & Ziegler has developed a unique, stable and reliable method to produce a highly pure form of n.c.a. Lu-177 which will be used by Alpha-9 for the clinical trials of its therapeutic candidates for solid and hematologic malignancies.

Lutetium-177 is a beta emitting radioisotope that can be linked to a variety of tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells.

“The supply contract with Canada-based Alpha-9 further underlines our outstanding expertise in supplying isotopes to the pharmaceutical industry. With production sites in Europe, Asia, and North America, we are excellently positioned to meet the growing demand for relevant isotopes and the associated development and production services,” explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.”

Alpha-9 is committed to developing its portfolio and exploring potential therapies to help patients. Alpha-9 is looking forward to its partnership with Eckert Ziegler and the potential that this partnership creates to advance radioligand therapy.

Targeted radionuclide therapy with Lutetium-177, currently under late-stage clinical development for several types of cancer, may provide a valuable alternative treatment option in the field of precision oncology.

About Eckert & Ziegler.

Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.

About Alpha-9 Theranostics

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles.

Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics

VANCOUVER, British Columbia, April 28, 2021 — Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. “We are delighted that Longitude and BVF are investing in Alpha-9,” said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. “These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.” David Hirsch, MD, PhD of Longitude Capital remarked, “Alpha9 is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential to deliver on the promise of precision oncology and we look forward to working with the Alpha-9 team to advance multiple programs into clinical trials.”

About Alpha-9

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers. For more information, please visit www.alpha9tx.com.

About Longitude Capital

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit www.longitudecapital.com or LinkedIn.